{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:16:06Z","timestamp":1778606166823,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR130780"],"award-info":[{"award-number":["NIHR130780"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Eat Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The OPEN feasibility trial testing olanzapine in anorexia nervosa (AN) in young people (YP) was not successful due to poor recruitment. This study aims to understand clinicians\u2019 views and experiences of using olanzapine in AN and the challenges in implementing the trial in National Health Service (NHS) clinical settings.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted qualitative interviews with eating disorders (ED) clinicians involved with the study (<jats:italic>n<\/jats:italic>\u2009=\u200911). Framework analysis was applied to qualitative data to identify barriers and facilitators to recruitment and study implementation. A web-based semi-structured Qualtrics survey was administered to ED clinicians (<jats:italic>n<\/jats:italic>\u2009=\u200924). Findings from the survey were used to corroborate and expand on the information derived from qualitative interviews.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Qualitative analysis identified four main themes: (1) <jats:italic>Acknowledging Service User (SU) \/ Family Concerns<\/jats:italic>, (2) <jats:italic>Prioritising person-centred care<\/jats:italic>, (3) <jats:italic>Limited Service Capacity<\/jats:italic> and (4) <jats:italic>Study eligibility criteria<\/jats:italic>. Subthemes are outlined accordingly. Clinicians appeared confident addressing SU concerns around olanzapine in clinical discussions, but timing was critical, and olanzapine was considered one aspect of treatment that needed to align with their holistic approach. Service pressures restricted opportunities for recruitment and the ability to offer regular review. At the same time, some YP were ineligible for the trial, as they were already taking olanzapine, or needed to be prescribed it more promptly than the study procedures allowed. Survey findings underlined confidence in prescribing and informing on olanzapine, the various possible benefits of olanzapine besides weight gain, and the importance of therapeutic alliances and informed consent. Both data sets highlight the need for further evidence on long-term safety, side effects and efficacy of olanzapine use for AN. Where clinical service capacity is at a premium, research implementation is not prioritised, particularly in intensive clinical settings.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Findings provide first-hand insight into individual and systemic challenges with research implementation in the NHS, which need to be considered when designing future clinical research studies. We emphasise a person-centred approach when discussing olanzapine to consider a holistic recovery from AN beyond weight-gain as an isolated outcome for improvement.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40337-024-01106-9","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T10:02:04Z","timestamp":1727431324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A feasibility trial of olanzapine for young people with Anorexia Nervosa (OPEN): clinicians\u2019 perspectives"],"prefix":"10.1186","volume":"12","author":[{"given":"Vanessa","family":"Kellermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ece","family":"Sengun Filiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olena","family":"Said","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Bentley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel W.T.","family":"Khor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mima","family":"Simic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dasha","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Treasure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubertus","family":"Himmerich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"issue":"1","key":"1106_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41380-021-01161-7","volume":"27","author":"M Solmi","year":"2022","unstructured":"Solmi M, Radua J, Olivola M, Croce E, Soardo L, Salazar de Pablo G, et al. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. Mol Psychiatry. 2022;27(1):281\u201395.","journal-title":"Mol Psychiatry"},{"issue":"10","key":"1106_CR2","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1017\/S0033291711000390","volume":"41","author":"E Attia","year":"2011","unstructured":"Attia E, Kaplan AS, Walsh BT, Gershkovich M, Yilmaz Z, Musante D, et al. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med. 2011;41(10):2177\u201382.","journal-title":"Psychol Med"},{"issue":"6","key":"1106_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/YCO.0000000000000360","volume":"30","author":"A Hilbert","year":"2017","unstructured":"Hilbert A, Hoek HW, Schmidt R. Evidence-based clinical guidelines for eating disorders: international comparison. Curr Opin Psychiatry. 2017;30(6):423\u201337.","journal-title":"Curr Opin Psychiatry"},{"issue":"4","key":"1106_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/YIC.0b013e328080ca31","volume":"22","author":"F Brambilla","year":"2007","unstructured":"Brambilla F, Garcia CS, Fassino S, Daga GA, Favaro A, Santonastaso P, et al. Olanzapine therapy in anorexia nervosa: psychobiological effects. Int Clin Psychopharmacol. 2007;22(4):197\u2013204.","journal-title":"Int Clin Psychopharmacol"},{"issue":"10","key":"1106_CR5","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1176\/appi.ajp.2008.07121900","volume":"165","author":"H Bissada","year":"2008","unstructured":"Bissada H, Tasca GA, Barber AM, Bradwejn J. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2008;165(10):1281\u20138.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"1106_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1176\/appi.ajp.2018.18101125","volume":"176","author":"E Attia","year":"2019","unstructured":"Attia E, Steinglass JE, Walsh BT, Wang Y, Wu P, Schreyer C, et al. Olanzapine Versus Placebo in Adult outpatients with Anorexia Nervosa: a Randomized Clinical Trial. Am J Psychiatry. 2019;176(6):449\u201356.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1106_CR7","first-page":"197","volume":"27","author":"W Spettigue","year":"2018","unstructured":"Spettigue W, Norris ML, Maras D, Obeid N, Feder S, Harrison ME, et al. Evaluation of the effectiveness and safety of Olanzapine as an adjunctive treatment for Anorexia Nervosa in adolescents: an open-label trial. J Can Acad Child Adolesc Psychiatry. 2018;27(3):197\u2013208.","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"issue":"3","key":"1106_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/cap.2010.0139","volume":"21","author":"V Kafantaris","year":"2011","unstructured":"Kafantaris V, Leigh E, Hertz S, Berest A, Schebendach J, Sterling WM, et al. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol. 2011;21(3):207\u201312.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"8","key":"1106_CR9","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/15622975.2023.2179663","volume":"24","author":"H Himmerich","year":"2023","unstructured":"Himmerich H, Lewis YD, Conti C, Mutwalli H, Karwautz A, Sj\u00f6gren JM, Uribe Isaza MM, Tyszkiewicz-Nwafor M, Aigner M, McElroy SL, Treasure J, Kasper S, WFSBP Task Force on Eating Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders. World J Biol Psychiatry. 2023;24(8):643\u2013706.","journal-title":"World J Biol Psychiatry"},{"issue":"9","key":"1106_CR10","doi-asserted-by":"publisher","first-page":"e031707","DOI":"10.1136\/bmjopen-2019-031707","volume":"9","author":"M Beykloo","year":"2019","unstructured":"Beykloo M, Nicholls D, Simic M, Brauer R, Mills E, Wong ICK. Survey on self-reported psychotropic drug prescribing practices of eating disorder psychiatrists for the treatment of young people with anorexia nervosa. BMJ Open. 2019;9(9):e031707.","journal-title":"BMJ Open"},{"key":"1106_CR11","doi-asserted-by":"crossref","unstructured":"Mutwalli H, Lewis YD, Conti C, Treasure J, Himmerich H. Pharmacological treatment and eating disorders. In: Robinson P, Wade T, Herpertz-Dahlmann B, Fernandez\u2010 Aranda F, Treasure J, Wonderlich S, editors. Eating disorders: an International Comprehensive View. Springer International Publishing.; 2023. pp. 1\u201322.","DOI":"10.1007\/978-3-030-97416-9_72-1"},{"issue":"3","key":"1106_CR12","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/erv.3060","volume":"32","author":"O Said","year":"2024","unstructured":"Said O, Sengun Filiz E, Stringer D, Applewhite B, Kellermann V, Mutwalli H, et al. Olanzapine for young PEople with aNorexia nervosa (OPEN): a protocol for an open-label feasibility study. Eur Eat Disord Rev. 2024;32(3):532\u201346.","journal-title":"Eur Eat Disord Rev"},{"key":"1106_CR13","doi-asserted-by":"publisher","unstructured":"Said O, Stringer D, Sengun Filiz E, Mutwalli H, Bektas S, Akkese MN et al. Olanzapine for young PEople with aNorexia nervosa (OPEN): results of a feasibility study. Available as pre-print version at https:\/\/doi.org\/10.21203\/rs.3.rs-4649545\/v1","DOI":"10.21203\/rs.3.rs-4649545\/v1"},{"issue":"4","key":"1106_CR14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/erv.2975","volume":"31","author":"M Phillips","year":"2023","unstructured":"Phillips M, \u0130nce B, Webb H, Dalton B, McCombie C, Irish M, et al. Autopsy of a failed trial part 1: a qualitative investigation of clinician\u2019s views on and experiences of the implementation of the DAISIES trial in UK-based intensive eating disorder services. Eur Eat Disord Rev. 2023;31(4):489\u2013504.","journal-title":"Eur Eat Disord Rev"},{"issue":"6 Pt 2","key":"1106_CR15","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1111\/1475-6773.12117","volume":"48","author":"MD Fetters","year":"2013","unstructured":"Fetters MD, Curry LA, Creswell JW. Achieving integration in mixed methods designs-principles and practices. Health Serv Res. 2013;48(6 Pt 2):2134\u201356.","journal-title":"Health Serv Res"},{"key":"1106_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4324\/9780203413081_chapter_9","volume-title":"Analysing qualitative data","author":"J Ritchie","year":"1994","unstructured":"Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In: Bryman A, Burgess R, G., editors. Analysing qualitative data. London: Routledge; 1994. pp. 173\u201394."},{"key":"1106_CR17","unstructured":"L. NVivo (Version 14: https:\/\/lumivero.com\/; 2023."},{"issue":"1","key":"1106_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40337-023-00801-3","volume":"11","author":"J Miskovic-Wheatley","year":"2023","unstructured":"Miskovic-Wheatley J, Bryant E, Ong SH, Vatter S, Le A, Touyz S, et al. Eating disorder outcomes: findings from a rapid review of over a decade of research. J Eat Disord. 2023;11(1):85.","journal-title":"J Eat Disord"},{"key":"1106_CR19","unstructured":"Kellermann V, Olive R*, Sengun Filiz E, Treasure J, Schmidt U, Simic M, Nicholls D et al. What does taking olanzapine mean to young people with anorexia nervosa and their families? Findings from the OPEN feasibility trial (submitted)."},{"issue":"4","key":"1106_CR20","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s40519-021-01281-7","volume":"27","author":"J Werz","year":"2022","unstructured":"Werz J, Voderholzer U, Tuschen-Caffier B. Alliance matters: but how much? A systematic review on therapeutic alliance and outcome in patients with anorexia nervosa and bulimia nervosa. Eat Weight Disord. 2022;27(4):1279\u201395.","journal-title":"Eat Weight Disord"},{"key":"1106_CR21","doi-asserted-by":"crossref","unstructured":"Dessain A, Bentley J, Treasure J, Schmidt U, Himmerich HIAIO. In: Himmerich H, editor. Patients\u2019 and carers\u2019 perspectives of psychopharmacological interventions targeting anorexia nervosa symptoms. Anorexia and bulimia nervosa InTech Open; 2019.","DOI":"10.5772\/intechopen.86083"},{"issue":"3","key":"1106_CR22","doi-asserted-by":"publisher","first-page":"e0278189","DOI":"10.1371\/journal.pone.0278189","volume":"18","author":"S Thorey","year":"2023","unstructured":"Thorey S, Blanchet C, Guessoum SB, Moro MR, Ludot M, Carretier E. Efficacy and tolerance of second-generation antipsychotics in anorexia nervosa: a systematic scoping review. PLoS ONE. 2023;18(3):e0278189.","journal-title":"PLoS ONE"},{"issue":"6","key":"1106_CR23","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s40519-020-01044-w","volume":"26","author":"R Bachner-Melman","year":"2021","unstructured":"Bachner-Melman R, de Vos JA, Zohar AH, Shalom M, Mcgilley B, Oberlin K, Murray L, Lamarre A, Dooley-Hash S. Attitudes towards eating disorders clinicians with personal experience of an eating disorder. Eat Weight Disord. 2021;26(6):1881\u201391. https:\/\/doi.org\/10.1007\/s40519-020-01044-w. Epub 2020 Oct 12. PMID: 33044728).","journal-title":"Eat Weight Disord"},{"issue":"6","key":"1106_CR24","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1370\/afm.1865","volume":"13","author":"TC Guetterman","year":"2015","unstructured":"Guetterman TC, Fetters MD, Creswell JW. Integrating quantitative and qualitative results in Health Science mixed methods Research through Joint displays. Ann Fam Med. 2015;13(6):554\u201361.","journal-title":"Ann Fam Med"},{"issue":"7","key":"1106_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/eat.22872","volume":"51","author":"TD Wade","year":"2018","unstructured":"Wade TD, Johnson C, Byrne SM. Randomized controlled psychotherapy trials in eating disorders: improving their conduct, interpretation and usefulness. Int J Eat Disord. 2018;51(7):629\u201336. https:\/\/doi.org\/10.1002\/eat.22872. Epub 2018 Apr 25. PMID: 29693749.","journal-title":"Int J Eat Disord"},{"key":"1106_CR26","doi-asserted-by":"publisher","unstructured":"Karwautz A, Zeiler M, Schwarzenberg J, Mairhofer D, Mitterer M, Truttmann S, Philipp J, Koubek D, Gl\u00fcder M, Wagner G, Malcher A, Sch\u00f6fbeck G, Laczkovics C, Rock HW, Zanko A, Imgart H, Banaschewski T, Fleischhaker C, Correll CU, Wewetzer C, Walitza S, Taurines R, Fekete S, Romanos M, Egberts K, Gerlach M. Therapeutic drug monitoring in adolescents with anorexia nervosa for safe treatment with adjunct olanzapine. Eur Eat Disord Rev. 2023 Aug;17. https:\/\/doi.org\/10.1002\/erv.3022. Epub ahead of print. PMID: 37592386.","DOI":"10.1002\/erv.3022"}],"container-title":["Journal of Eating Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40337-024-01106-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40337-024-01106-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40337-024-01106-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T10:10:08Z","timestamp":1727431808000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeatdisord.biomedcentral.com\/articles\/10.1186\/s40337-024-01106-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1106"],"URL":"https:\/\/doi.org\/10.1186\/s40337-024-01106-9","relation":{},"ISSN":["2050-2974"],"issn-type":[{"value":"2050-2974","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"27 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Health and Social Care Research Ethics Committee B (Reference 22\/NI\/0010) and by the Health Research Authority (HRA) on the 11th of April 2022. Human Ethics and Consent to Participate declarations: All participants provided written consent to participate before data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants consented to publish data from interviews conducted. No identifiable information is included in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HH is the chief investigator for an NIHR HTA-funded feasibility study testing olanzapine in young patients with anorexia nervosa (AN) and the principal investigator of a COMPASS Pathways-funded and -sponsored proof-of-concept study testing psilocybin in AN.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"146"}}